阿利罗库单抗
载脂蛋白B
内科学
PCSK9
内分泌学
医学
脂蛋白(a)
脂蛋白
可欣
他汀类
Evolocumab公司
低密度脂蛋白受体
胆固醇
载脂蛋白A1
作者
Qidi Ying,Dick C. Chan,Jing Pang,Santica M. Marcovina,P. Hugh R. Barrett,Gerald F. Watts
摘要
Inhibition of proprotein convertase subtilisin/kexin type 9 with alirocumab decreases plasma lipoprotein(a) [Lp(a)] levels. The kinetic mechanism for lowering Lp(a) by alirocumab may differ according to pre-treatment apolipoprotein(a) [apo(a)] levels.The effect of 12-week alirocumab (150 mg subcutaneously fortnightly) on the kinetics of apo(a) was compared in statin-treated patients with high (n = 10) and very high Lp(a) concentrations (n = 11).In patients with high apo(a) concentrations, alirocumab lowered plasma apo(a) pool size (-17%, p < 0.01) chiefly by increasing the fractional catabolic rate (FCR) of apo(a) (+27%, p < 0.001). By contrast in patients with very high apo(a) concentrations, alirocumab significantly lowered plasma apo(a) pool size (-32%, p < 0.001) by both increasing apo(a) FCR (+30%, p < 0.001) and lowering production rate (-11%, p < 0.05).In statin-treated patients with very high apo(a) concentrations, alirocumab lowers plasma Lp(a) concentration by a dual mode of action that increases the clearance and decreases the production of Lp(a) particles.
科研通智能强力驱动
Strongly Powered by AbleSci AI